AU2016290761A1 - Use of modified FC fragments in immunotherapy - Google Patents

Use of modified FC fragments in immunotherapy

Info

Publication number
AU2016290761A1
AU2016290761A1 AU2016290761A AU2016290761A AU2016290761A1 AU 2016290761 A1 AU2016290761 A1 AU 2016290761A1 AU 2016290761 A AU2016290761 A AU 2016290761A AU 2016290761 A AU2016290761 A AU 2016290761A AU 2016290761 A1 AU2016290761 A1 AU 2016290761A1
Authority
AU
Australia
Prior art keywords
immunotherapy
fragments
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2016290761A
Other versions
AU2016290761B2 (en
Inventor
Abdessatar Chtourou
Christophe De Romeuf
Alexandre Fontayne
Philippe Mondon
Céline Monnet-Mars
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1556399A external-priority patent/FR3038517B1/en
Application filed by LFB SA filed Critical LFB SA
Publication of AU2016290761A1 publication Critical patent/AU2016290761A1/en
Application granted granted Critical
Publication of AU2016290761B2 publication Critical patent/AU2016290761B2/en
Priority to AU2022204834A priority Critical patent/AU2022204834A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2016290761A 2015-07-06 2016-07-06 Use of modified FC fragments in immunotherapy Active AU2016290761B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022204834A AU2022204834A1 (en) 2015-07-06 2022-07-06 Use of modified Fc fragments in immunotherapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1556399A FR3038517B1 (en) 2015-07-06 2015-07-06 USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
FR1556399 2015-07-06
PCT/FR2016/051708 WO2017006052A2 (en) 2015-07-06 2016-07-06 Use of modified fc fragments in immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022204834A Division AU2022204834A1 (en) 2015-07-06 2022-07-06 Use of modified Fc fragments in immunotherapy

Publications (2)

Publication Number Publication Date
AU2016290761A1 true AU2016290761A1 (en) 2018-02-22
AU2016290761B2 AU2016290761B2 (en) 2022-04-07

Family

ID=54937180

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016290761A Active AU2016290761B2 (en) 2015-07-06 2016-07-06 Use of modified FC fragments in immunotherapy
AU2022204834A Pending AU2022204834A1 (en) 2015-07-06 2022-07-06 Use of modified Fc fragments in immunotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022204834A Pending AU2022204834A1 (en) 2015-07-06 2022-07-06 Use of modified Fc fragments in immunotherapy

Country Status (8)

Country Link
US (1) US20180355034A1 (en)
EP (1) EP3319989A2 (en)
JP (3) JP2018524355A (en)
CN (2) CN113817049A (en)
AU (2) AU2016290761B2 (en)
CA (1) CA2990354A1 (en)
FR (1) FR3038517B1 (en)
WO (1) WO2017006052A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY160298A (en) 2010-12-30 2017-02-28 Lab Francais Du Fractionnement Glycols as pathogen inactivating agents
EP3016729B1 (en) 2013-07-05 2020-03-25 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Affinity chromatography matrix
FR3038517B1 (en) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
AU2018218345A1 (en) * 2017-02-10 2019-08-29 Genmab B.V. Polypeptide variants and uses thereof
FR3064007A1 (en) * 2017-03-20 2018-09-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies ANTIBODIES FOR THE TREATMENT OF CANCERS
FR3075200B1 (en) * 2017-12-15 2022-12-23 Lab Francais Du Fractionnement VARIANTS WITH FC FRAGMENT HAVING INCREASED AFFINITY FOR FCRN AND INCREASED AFFINITY FOR AT LEAST ONE FC FRAGMENT RECEIVER
EP3845558A4 (en) * 2018-08-29 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-molecule
CN111825770B (en) * 2019-04-16 2023-06-09 成都医学院 Long-acting interleukin 21-Fc fusion protein and application thereof
WO2021057726A1 (en) * 2019-09-23 2021-04-01 南开大学 SCREENING OF FC SPECIFICALLY BINDING TO FCγR BY USING MAMMALIAN DISPLAY
WO2023104128A1 (en) * 2021-12-09 2023-06-15 上海宝济药业有限公司 Fc polypeptide having altered glycosylation modification

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8421551D0 (en) 1984-08-24 1984-09-26 Ici Plc Water-soluble dye
DK2270147T4 (en) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd METHOD OF MONITORING THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE
FR2807767B1 (en) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
ES2330330T3 (en) 2000-06-28 2009-12-09 Glycofi, Inc. PROCEDURE OF PRODUCTION OF MODIFIED GLUCOPROTEINS.
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
FR2816319B1 (en) 2000-11-08 2004-09-03 Millegen USE OF DNA MUTAGEN POLYMERASE FOR THE CREATION OF RANDOM MUTATIONS
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
US6994292B2 (en) 2002-10-18 2006-02-07 The Procter & Gamble Company Dispensing apparatus for web material
US7355008B2 (en) * 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050160485A1 (en) 2003-03-18 2005-07-21 Kyowa Hakko Kogyo Co., Ltd. Mouse in which genome is modified
US20040219143A1 (en) 2003-04-30 2004-11-04 Bluth Martin Heath Methods for recombinant immunoglobulin treatment
WO2005035778A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
CA2608818A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
DK1945665T3 (en) 2005-10-21 2012-02-06 Genzyme Corp Antibody-based therapy agents with elevated ADCC activity
NZ568433A (en) 2005-10-21 2012-07-27 Gtc Biotherapeutics Inc Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007099988A1 (en) 2006-02-28 2007-09-07 Kyowa Hakko Kogyo Co., Ltd. α-1,6-FUCOSYLTRANSFERASE MUTANT AND USE THEREOF
WO2008151088A2 (en) * 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
TW201326209A (en) * 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
EP3485909A1 (en) * 2011-12-19 2019-05-22 The Rockefeller University Non-sialylated anti-inflammatory polypeptides
KR102104686B1 (en) * 2012-01-10 2020-04-24 바이오젠 엠에이 인코포레이티드 Enhancement of transport of therapeutic molecules across the blood brain barrier
EP3470433A1 (en) * 2012-04-27 2019-04-17 Bioatla, LLC Modified antibody regions and uses thereof
CA2903258C (en) * 2013-03-15 2019-11-26 Amgen Inc. Heterodimeric bispecific antibodies
ES2742682T3 (en) * 2013-12-24 2020-02-17 Argenx Bvba FCRN antagonists and methods of use
FR3035879A1 (en) * 2015-05-07 2016-11-11 Lab Francais Du Fractionnement MUTANTS FC WITH MODIFIED FUNCTIONAL ACTIVITY
FR3038517B1 (en) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY

Similar Documents

Publication Publication Date Title
EP3245291A4 (en) Novel micro-dystrophins and related methods of use
AU2016290761A1 (en) Use of modified FC fragments in immunotherapy
EP3177322A4 (en) Anti-trem2 antibodies and methods of use thereof
EP3097122A4 (en) Binding proteins and methods of use thereof
EP3237450A4 (en) Anti-mertk agonistic antibodies and uses thereof
EP3160498A4 (en) Il-15-based molecules and methods of use thereof
EP3125960A4 (en) Click-crosslinked hydrogels and methods of use
EP3218443A4 (en) Refrigerant compositions and methods of use
EP3122761A4 (en) Engineered light-activated anion channel proteins and methods of use thereof
EP3112436A4 (en) Polishing composition
EP3131566A4 (en) Bi-terminal pegylated integrin-binding peptides and methods of use thereof
EP3116911B8 (en) Anti-mcam antibodies and associated methods of use
EP3383917A4 (en) Novel anti-claudin antibodies and methods of use
EP3015526A4 (en) Halo-olefin composition and use therefor
EP3177638A4 (en) Targeting peptides and methods of use
EP3216562A4 (en) Polishing method and composition for polishing
EP3134121A4 (en) Novel anti-rnf43 antibodies and methods of use
EP3226898A4 (en) Bromodomain inhibitor as adjuvant in cancer immunotherapy
EP3215182A4 (en) Combination immunotherapy
EP3394098A4 (en) Anti-myostatin antibodies and methods of use
EP3124570A4 (en) Polishing composition
EP3389705A4 (en) Listeria-based immunotherapy and methods of use thereof
EP3221087A4 (en) Bonded abrasive articles and methods of manufacture
EP3189079A4 (en) Novel anti-mfi2 antibodies and methods of use
EP3107569A4 (en) Anti-acth antibodies and use thereof